Pages that link to "Q77178375"
Jump to navigation
Jump to search
The following pages link to Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects (Q77178375):
Displaying 37 items.
- Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children (Q24197682) (← links)
- Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children (Q24247433) (← links)
- Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma (Q24247489) (← links)
- Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R (Q24673057) (← links)
- The role of mast cells in asthma (Q28191630) (← links)
- Cysteinyl leukotrienes and their receptors; emerging concepts (Q28243252) (← links)
- Newer Perspectives of Childhood Asthma (Q28397893) (← links)
- Leukotriene-receptor antagonists (Q33534380) (← links)
- Hyperresponsiveness in the human nasal airway: new targets for the treatment of allergic airway disease (Q33855065) (← links)
- Montelukast: a review of its therapeutic potential in persistent asthma (Q33914371) (← links)
- New medications for asthma (Q34114478) (← links)
- Efficacy of antileukotriene agents in asthma management (Q34293779) (← links)
- Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. (Q34424227) (← links)
- Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. (Q34558685) (← links)
- CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells (Q34662206) (← links)
- Differential regulation of cysteinyl leukotriene receptor signaling by protein kinase C in human mast cells (Q34971386) (← links)
- Pranlukast: a review of its use in the management of asthma (Q35109122) (← links)
- Benefit-risk assessment of antileukotrienes in the management of asthma. (Q35123390) (← links)
- Contrasting effects of allergen challenge on airway responsiveness to cysteinyl leukotriene D(4) and methacholine in mild asthma (Q35535288) (← links)
- Role of human mast cells and basophils in bronchial asthma (Q36287476) (← links)
- Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists (Q36370341) (← links)
- Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells (Q36711106) (← links)
- P2Y6 receptors require an intact cysteinyl leukotriene synthetic and signaling system to induce survival and activation of mast cells (Q37041271) (← links)
- Mast Cells in Allergic Asthma and Beyond (Q37794115) (← links)
- Allergen-induced airway inflammation and its therapeutic intervention (Q39382492) (← links)
- Leukotriene D(4) induces gene expression in human monocytes through cysteinyl leukotriene type I receptor (Q41442898) (← links)
- Development of 2,2-dimethylchromanol cysteinyl LT1 receptor antagonists (Q42536290) (← links)
- Pharmacological profile of MEN91507, a new CysLT(1) receptor antagonist (Q44145477) (← links)
- Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity. (Q47669026) (← links)
- Selective optimization of Pranlukast to farnesoid X receptor modulators (Q57790748) (← links)
- Eicosanoid Control Over Antigen Presenting Cells in Asthma (Q58764843) (← links)
- The effect of Cys LT1 receptor blockade on airway responses to allergen (Q73167976) (← links)
- Leukotriene modifiers: what is their position in asthma therapy? (Q77178360) (← links)
- [Use of the mouse to unravel allergic asthma: a review of the pathogenesis of allergic asthma in mouse models and its similarity to the condition in humans] (Q81520330) (← links)
- Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method (Q83387296) (← links)
- COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity (Q90288923) (← links)
- Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism (Q91142640) (← links)